Off-label use of transmucosal ketamine as a rapid-acting antidepressant: A retrospective chart review

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2667-2673

  Nguyen, Linda ^a,b   Marshalek, Patrick J ^b   Weaver, Cory B ^a   Cramer, Kathy J ^b,c   Pollard, Scott E ^b,d   Matsumoto, Rae R ^a,b,e  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT MORRIS UNIVERSITY   (United States)

^d West Park Hospital   (United States)

^e TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Depression; Glutamate; Ketamine; Mood disorder; NMDA receptor; Treatment resistance

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; FOLIC ACID; KETAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AGED; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FEMALE; HEADACHE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUCOSAL DRUG ADMINISTRATION; OFF LABEL DRUG USE; POLYPHARMACY; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

EID: 84945176342     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S88569     Document Type: Review

References (32)

1. Depression. Fact sheet No 369 [webpage on the Internet]. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/. Accessed January 14, 2014.
2. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7 Suppl 1:S23-S28.
3. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369-388.
4. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354.
5. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605-1611.
6. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142.
7. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34(4):287-293.
8. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011; 191(2):122-127.
9. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
10. Zarate CA Jr., Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946.
11. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Rosier JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.
12. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256.
13. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145.
14. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663-3676.
15. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693-704.
16. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56-61.
17. Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958-965.
18. Iglewicz A, Morrison K, Nelesen KA, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics. 2015;56(4):329-337.
19. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010;13(7):903-908.
20. Chilukuri H, Reddy MP, Pathapati RM, Manu AN, Jollu S, Shaik AB. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 2014;36(1):71-76.
21. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012;169(8):868-869.
22. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970-976.
23. Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013; 16(9):2111-2117.
24. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 2010;43(1):33-35.
25. Glue P, Gulati A, Le Nedelec M, Duffull S. Dose- and exposure-response to ketamine in depression. Biol Psychiatry. 2011;70(4):e9-e10; author reply e11-e12.
26. Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 2012;15(4):400-403.
27. McNulty JP, Hahn K. Compounded oral ketamine. Int J Pharm Compd. 2012;16(5):364-368.
28. DiBonaventura MD, Wagner JS, Girman CJ, et al. Multinational Internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397-406.
29. Yawn BP, Colice GL, Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2012;7:495-502.
30. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24(1):37-43.
31. American Psychiatric Association. Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington: American Psychiatric Association; 2000.
32. Campbell RJ. Campbell’s Psychiatric Dictionary. 9th ed. New York: Oxford University Press; 2009